Datamonitor Healthcare Oncology Disease Analysis: Acute Myeloid Leukemia (AML)

October 13, 2021

Since 2017, there have been nine new drugs approved for AML in the US, dramatically changing the treatment landscape. Gone is the era where all front-line patients received either 7+3 chemotherapy or a hypomethylating agent (decitabine or azacitidine). Many of the new therapies target specific segments of AML or patients with specific mutations. As such, there is currently little competition between the new therapies, but that will change as therapies receive label expansions and new competitor therapies are approved. 

Two FLT3 inhibitors have been approved for FLT3-mutated AML: Rydapt for front-line patients eligible for intensive chemotherapy, and Xospata for relapsed/refractory patients. Rydapt may soon face competition in the front-line FLT3 setting as quizartinib, crenolanib, and Xospata are being evaluated in combination with standard chemotherapy and as single-agent maintenance therapies following either chemotherapy consolidation or hematopoietic stem cell transplant. Approval in the lucrative maintenance setting would give these drugs a favorable long-term commercial outlook. Approximately 25–30% of AML patients have an FLT3 mutation. 

This Datamonitor Healthcare report contains a Disease Analysis module.

Indications Covered:

Acute Myelogenous Leukemia (AML)